Translational Psychiatry
September 20, 2016
Daniel M. Rotroff, Daniel Corum, Alison A. Motsinger‐Reif et al.
99 citations
Ketamine, at sub-anesthetic doses, is reported to rapidly decrease depression symptoms in patients with treatment-resistant major depressive disorder (MDD). Many patients do not respond to currently available antidepressants, (for example, serotonin reuptake inhibitors), making ketamine and its enantiomer, esketamine, potentially attractive options for treatment-resistant MDD. Although...
April 20, 2016
Fangbo Lin, Deren Hou, Qiuping Tang
8 citations
OBJECTIVE: The pathogenesis and etiology of still remain unknown. Current evidence suggests that the occurrence of depression may be related to a reduced secretion of neurotransmitters, neuronal apoptosis, inflammation, intestinal flora and other factors. Although the commonly used antidepressants such as SSRIs, SNRIs, NaSSA, and SARIs produce some therapeutic effects, they fail to relieve the...
Biological Psychiatry
November 4, 2015
Jaskaran Singh, Maggie Fedgchin, Ella Daly et al.
466 citations
BACKGROUND: The purpose of this study was to assess the efficacy and safety and to explore the dose response of esketamine intravenous (IV) infusion in patients with treatment-resistant depression (TRD). METHODS: This multicenter, randomized, placebo-controlled trial was conducted in 30 patients with TRD. Patients were randomly assigned 1:1:1 to receive an IV infusion of .20 mg/kg or .40 mg/kg...
Pharmacopsychiatry
December 11, 2009
Georgios Paslakis, Morin Gilles, Andreas Meyer‐Lindenberg et al.
66 citations
We intended to assess safety, response to treatment and time to response of 1.25 mg/kg oral S-ketamine as add-on to standard antidepressants in four depressed patients. Two patients with melancholic depression responded early and stayed in remission, while two patients with distinct somatic symptoms, chronicity or atypical features did not respond. The limited number of patients does not allow...
The World Journal of Biological Psychiatry
2009
Robert Paul, Nadine Schaaff, Frank Padberg et al.
Recent studies with intravenous infusion of the NMDA receptor antagonist ketamine showed robust and rapid antidepressant effects within hours after treatment. Ketamine is a racemic mixture consisting of two enantiomers, R- and S-ketamine. In contrast to ketamine, S-ketamine is reported to be less prone to psychomimetic side effects, such as derealisation and hallucinations. In this report we...
Ella Daly, Jaskaran Singh, Maggie Fedgchin et al.
Background: Intravenous ketamine and esketamine (ESK) produce rapid antidepressant action in treatment-resistant depression (TRD) patients, however dose response is not known. Study assessed efficacy, dose response and safety of intranasal ESK and ability to sustain response with gradual tapering of treatment frequency. Methods: In the Panel A (conducted in USA and Belgium) of this...
Jun Jing, Meng-Ying Zhang, Wei-hong Yin et al.
preprint
Abstract Objective To observe the effects of esketamine on postoperative depression and pain indicators in individuals undergoing total laparoscopic hysterectomy. Methods 135 patients undegoing total laparoscopic hysterectomy were recruited and randomly allocated to three groups. Finally, a total of 127 patients were selected into the statistical analysis, with the final grouping information as...
Muyan Zuo, Yaozu Li, John P Williams et al.
preprint
Purpose: Depression combined with insomnia is a complex bidirectional relationship that is more difficult to treat versus a single disorder, and there is a lack of effective treatments available. In this study, we carried out a novel way to simultaneously intervene in depression combined with insomnia and examined functional magnetic resonance imaging (fMRI) to help further elucidate the...
Shurong Li, Zhifang Zhuo, Renwei Li et al.
preprint
Abstract Background Postpartum depression (PPD) after cesarean delivery is a common complication. Esketamine's effects on PPD in women undergoing cesarean section remain contradictory, despite ketamine's prophylactic effects. This study evaluated the effect of esketamine as an adjunct to patient-controlled intravenous analgesia (PCIA) to prevent PPD in women undergoing caesarean section....
Hannah Tramontano, Jeffrey Fetter, Mohamed Wagdy ElSayed
preprint
Background: Borderline Personality Disorder (BPD) affects 1.35% of the population and is frequently comorbid with Major Depressive Disorder (MDD), which is frequently treatment-resistant (TRD). Patients with comorbid illness have worse treatment outcomes and functional impairment. Esketamine could ameliorate symptoms of both illnesses. Methods: We conducted a retrospective chart review of...